|
DSMZ
kcl22 s acc519 cell lines Kcl22 S Acc519 Cell Lines, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kcl22+cell+lines/KCL-22/pmc12541237-41-3-10 Average 93 stars, based on 1 article reviews
kcl22 s acc519 cell lines - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
DSMZ
kcl22 cell line ![]() Kcl22 Cell Line, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kcl22+cell+lines/KCL-22/pmc11994880-299-10-32 Average 94 stars, based on 1 article reviews
kcl22 cell line - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
DSMZ
leukemic cell line kcl22 ![]() Leukemic Cell Line Kcl22, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kcl22+cell+lines/KCL-22/pm39182842-77-22-30 Average 94 stars, based on 1 article reviews
leukemic cell line kcl22 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
JCRB Cell Bank
cml cell lines kcl22 ![]() Cml Cell Lines Kcl22, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kcl22+cell+lines/kcl22+cells/pm34875342-40-1-11 Average 90 stars, based on 1 article reviews
cml cell lines kcl22 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
ATCC
kcl22 cell lines ![]() Kcl22 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kcl22+cell+lines/KU812/pmc08595379-81-3-9 Average 95 stars, based on 1 article reviews
kcl22 cell lines - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
DSMZ
cell line kcl22 ![]() Cell Line Kcl22, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kcl22+cell+lines/kcl+22/pmc08493398-101-17-62 Average 90 stars, based on 1 article reviews
cell line kcl22 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
KinaSense LLC
cml cell lines kcl22 and kcl22-ir ![]() Cml Cell Lines Kcl22 And Kcl22 Ir, supplied by KinaSense LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/kcl22+cell+lines/cml+cell+lines+kcl22+and+kcl22+ir/pmc06312196-305-14-16 Average 90 stars, based on 1 article reviews
cml cell lines kcl22 and kcl22-ir - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: CML‐derived cell lines. In particular, name of cell line, cell type, sex and age of patient at time of establishment of cell line, disease status, year of establishment of cell line, source of specimen as indicated in the original publication and type of BCR,ABL1 fusion are indicated (BC = blastic crisis, BCP = B‐Cell Precursor, B‐LCL = B‐lymphoblastoid cell line (EBV + ), BM = bone marrow, BMT = bone marrow transplantation, F = female, M = male, NA = not available, R = relapse, PB = peripheral blood, PE = pleural effusion).
Article Snippet: This observation can be attributed to the fact that the
Techniques: Transplantation Assay
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: Panel of images illustrating the seven different treatment conditions of K562, LAMA84, and KCL22 cell lines obtained using the Invitrogen EVOS XL Core Imaging System with a 20× zoom. Areas of the well that best showed the cellular conditions were selected (including color, shape, size, and the formation of dead cell clusters). Panel A1, A2, A3: Control at 20× zoom in the three cell lines; Panel B1, B2, B3: DMSO at 20X zoom in the three cell lines; Panel C1, C2, C3: imatinib at 20× zoom in the three cell lines; Panel D1, D2, D3: nilotinib at 20× zoom in the three cell lines; Panel E1, E2, E3: dasatinib at 20× zoom in the three cell lines; Panel F1, F2, F3: bosutinib at 20× zoom in the three cell lines; Panel G1, G2, G3: ponatinib at 20× zoom in the three cell lines. Red arrows indicate significantly larger sized cells; blue arrow indicate cell clusters; orange arrows indicate larger sized cells; green arrows indicate irregularly shaped cells; blue boxes highlight apoptotic bodies. (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib).
Article Snippet: This observation can be attributed to the fact that the
Techniques: Imaging, Control
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: The average area, diameter, and circularity resulting from each treatment in the three cell lines utilized. Values that have shown statistically significant differences during comparison are highlighted in green. (BOSU, bosutinib; CTR, control; DASA, dasatinib; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; PONA, ponatinib; TKIs, tyrosine kinase inhibitors). (Two Way ANOVA).
Article Snippet: This observation can be attributed to the fact that the
Techniques: Comparison, Control
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: Cells viability (%) measured by MTT assay in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).
Article Snippet: This observation can be attributed to the fact that the
Techniques: MTT Assay, Comparison, Control
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: Number of cells measured by CCK8 assay in the three cell lines considered, K562, LAMA84 and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).
Article Snippet: This observation can be attributed to the fact that the
Techniques: CCK-8 Assay, Comparison, Control
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: Extracellular glutamate concentration (μM) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA: imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).
Article Snippet: This observation can be attributed to the fact that the
Techniques: Concentration Assay, Comparison, Control
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: Expression of BCR::ABL1 transcript (normalised for GAPDH) in the three cell lines considered, K562, LAMA84 and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).
Article Snippet: This observation can be attributed to the fact that the
Techniques: Expressing, Comparison, Control
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: Expression of CD33 transcript (normalized for GAPDH) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).
Article Snippet: This observation can be attributed to the fact that the
Techniques: Expressing, Comparison, Control
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: Expression of CD11b transcript (normalized for GAPDH) in the three cell lines considered, K562, LAMA84, and KCL22, representative of the comparison across individual treatment conditions (CTR, control; DMSO, dimethylsulfoxide; IMA, imatinib; NILO, nilotinib; DASA, dasatinib; BOSU, bosutinib; PONA, ponatinib) (Two‐way ANOVA with Tukey's post hoc test).
Article Snippet: This observation can be attributed to the fact that the
Techniques: Expressing, Comparison, Control
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: Panel of images illustrating asciminib treatment of K562, LAMA84, and KCL22 cell lines obtained using the Invitrogen EVOS XL Core Imaging System with a 20× zoom. Areas of the well that best showed the cellular conditions were selected (including color, shape, size, and the formation of dead cell clusters). Panel A1, A2, A3: Control at 20× zoom in the three cell lines; Panel B1, B2, B3: asciminib at 20× zoom in the three cell lines. Red arrows indicate significantly larger sized cells; blue arrow indicate cell clusters; orange arrows indicate larger sized cells; green arrows indicate irregularly shaped cells. (CTR, control; ASCI, asciminib).
Article Snippet: This observation can be attributed to the fact that the
Techniques: Imaging, Control
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: The average area, diameter, and circularity resulting from asciminib treatment in the three cell lines utilized. Values that have shown statistically significant differences during comparison are highlighted in green. (ASCI, asciminib; CTR, control). (Two Way ANOVA).
Article Snippet: This observation can be attributed to the fact that the
Techniques: Comparison, Control
Journal: Cell Biology International
Article Title: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
doi: 10.1002/cbin.70007
Figure Lengend Snippet: Cell viability (%) measured by MTT assay (A), number of cells measured by CCK8 assay (B), extracellular glutamate concentration (μM) (C) and expression of BCR::ABL1 (D), CD33 (E) and CD11b (F) transcripts all normalized for GAPDH in the three cell lines considered, K562, LAMA84 and KCL22, following asciminib treatment. (CTR, control; ASCI, asciminib) (Two‐way ANOVA with Tukey's post hoc test).
Article Snippet: This observation can be attributed to the fact that the
Techniques: MTT Assay, CCK-8 Assay, Concentration Assay, Expressing, Control
Journal: Blood Cancer Journal
Article Title: Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia
doi: 10.1038/s41408-021-00572-7
Figure Lengend Snippet: A Expression of isolated γδT cells was determined by CFSE-labeling. CFSE-labeled γδT cells were co-cultured with BCR-AB L-knockdown KCL22 cells (black bar) or untreated KCL22 cells (open bar). Simvastatin-pretreated, zoledronate-pretreated, or BCR-AB L siRNA-pretreated KCL22 cells were used as the targets for γδT cells at a ratio of 1:1. Zoledronate (Zometa, 5 μM) but not simvastatin (100 nM) rendered KCL22 cell proliferation. B Expression of TNF-α, IFN-γ, and perforin release of isolated γδT cells from six healthy donors was determined by ELISA after co-culture with BCR-ABL siRNA-, TKI-, simvastatin-treated, or untreated K562 cells for 24 h. Treatment with IPP (0.5 μM) was used as a control to activate γδT cells. The ex-vivo killing assays were performed using isolated ( C ) γδT cells and ( D ) naïve γδT cells isolated from healthy donors. The targets could be untreated KU812 cells, or KU812 pretreated with BCR-ABL -specific siRNA or zoledronate. The incubation time for target-γδT cells and for target-naïve subset was 4 h and 24 h, respectively. One-way ANOVA was used for comparison between multiple groups, and paired t test was used to compare selected groups. Statistical significances between these groups are marked with asterisk. Data were presented as mean values ± SD. Data comparison was performed by the paired t test. Statistical significance was defined by * p < 0.05, ** p < 0.01, and *** p < 0.001.
Article Snippet: K562, KU812, and
Techniques: Expressing, Isolation, Labeling, Cell Culture, Knockdown, Enzyme-linked Immunosorbent Assay, Co-Culture Assay, Control, Ex Vivo, Incubation, Comparison
Journal: American Journal of Cancer Research
Article Title: Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I -compound mutations
doi:
Figure Lengend Snippet: Cell lines and culture conditions
Article Snippet: Patients’ characteristics: CML samples used for in vitro studies and response to ‘asciminib+ponatinib’ table ft1 table-wrap mode="anchored"
Techniques: Cell Culture, Produced
Journal: American Journal of Cancer Research
Article Title: Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I -compound mutations
doi:
Figure Lengend Snippet: Asciminib and ponatinib synergize in producing growth inhibition in BCR-ABL1+ cell lines. The human CML cell lines KU812, K562, KCL22 and KCL22T315I (A) and Ba/F3 cells expressing various BCR-ABL1-mutations (Ba/F3p210T315I, Ba/F3p210T315I/E255V, Ba/F3p210T315I/F359V, Ba/F3p210T315I/F311L, Ba/F3p210T315I/G250E) or untransfected Ba/F3 cells supplemented with 10 ng/ml IL-3 (B) were kept in control medium or in the presence of asciminib (■-■), ponatinib (●-●), or a combination of both drugs at a fixed ratio (▲-▲) for 48 hours before 3H-thymidine-uptake was evaluated. Results are calculated as percent of control and represent the mean ± S.D. of triplicates. (C) The nature of drug interaction (additive versus synergistic) shown in (A) and (B) was determined for each experiment by calculating combination index (CI) values using Calcusyn software. A CI value of 1 indicates an additive effect, whereas CI values below 1 indicate synergistic drug effects. Examples are shown for K562 and KU812 as well as Ba/F3p210T315I and Ba/F3p210T315I/G250E cells as indicated.
Article Snippet: Patients’ characteristics: CML samples used for in vitro studies and response to ‘asciminib+ponatinib’ table ft1 table-wrap mode="anchored"
Techniques: Inhibition, Expressing, Control, Software
Journal: American Journal of Cancer Research
Article Title: Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I -compound mutations
doi:
Figure Lengend Snippet: Asciminib and ponatinib synergize in producing apoptosis in BCR-ABL1+ cell lines. KU812, K562 and KCL22T315I (A) and Ba/F3 cells expressing various BCR-ABL1-mutations (Ba/F3p210T315I, Ba/F3p210T315I/E255V, Ba/F3p210T315I/F359V, Ba/F3p210T315I/F311L, Ba/F3p210T315I/G250E) (B) were kept in control medium or in the presence of asciminib, ponatinib or a combination of both drugs as indicated for 48 hours before apoptosis was determined by Annexin V-FITC/DAPI staining and flow cytometry. One typical experiment (left panels) or the mean ± S.D. of three independent experiments. (right panels) are shown. Asterisk (right panels): P<0.05 compared to control.
Article Snippet: Patients’ characteristics: CML samples used for in vitro studies and response to ‘asciminib+ponatinib’ table ft1 table-wrap mode="anchored"
Techniques: Expressing, Control, Staining, Flow Cytometry
Journal: American Journal of Cancer Research
Article Title: Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I -compound mutations
doi:
Figure Lengend Snippet: Asciminib and ponatinib synergize in inhibiting CRKL phosphorylation in human CML cell lines. KU812, K562, KCL22 and KCL22T315I were kept in control medium (Control) or in the presence of asciminib (Asci), ponatinib (Pona) or a combination (Combi) of both drugs as indicated for 4 hours before expression of p-CRKL and β-tubulin (loading control) were analyzed by Western blotting.
Article Snippet: Patients’ characteristics: CML samples used for in vitro studies and response to ‘asciminib+ponatinib’ table ft1 table-wrap mode="anchored"
Techniques: Phospho-proteomics, Control, Expressing, Western Blot
Journal: ChemMedChem
Article Title: Alkynylnicotinamide-based compounds as ABL1 inhibitors with potent activities against drug-resistant CML harboring ABL1(T315I) mutant kinase.
doi: 10.1002/cmdc.201700829
Figure Lengend Snippet: Calculated LogP and anti-proliferation activities of alkynyl analogs
Article Snippet: Evaluation of compounds activity against ABL1 and ABL1(T315I) inside CML cell lines KCL22 and
Techniques:
Journal: ChemMedChem
Article Title: Alkynylnicotinamide-based compounds as ABL1 inhibitors with potent activities against drug-resistant CML harboring ABL1(T315I) mutant kinase.
doi: 10.1002/cmdc.201700829
Figure Lengend Snippet: Inhibition of cellular ABL1 activity by imatinib, ponatinib and HSN compounds
Article Snippet: Evaluation of compounds activity against ABL1 and ABL1(T315I) inside CML cell lines KCL22 and
Techniques: Inhibition, Activity Assay